Previously, he was Global Devlopment Unit Head for Immunology, Hepatology and Dermatology at Novartis and held several executive and senior positions at Bristol Myers Squibb, including Head of ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

The report’s highlight is that SARS-CoV-2 possibly emerged from a laboratory leak. The report found this conclusion on ...

The House Select Subcommittee on the Coronavirus Pandemic recently issued its final After Action Review of the COVID-19 ...

Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID-19 and Ebola -- while also minimizing side effects and reducing the odds of ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, ...

Highly pathogenic avian influenza has been found in samples taken from snow geese at Sloughs Wildlife Management Area (WMA) ...

Data since the early 1900s indicate that influenza might increase the risk for cardiovascular complications. Today, we know ...